Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus

Next Previous
Trial Profile

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Stroke; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CANVAS-R; CANVAS-Renal
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 01 Apr 2025 Results of pooled analysis from CANVAS Program and CREDENCE assessing cardiovascular, kidney and safety outcomes with canagliflozin in older adults, published in the Diabetes, Obesity and Metabolism.
  • 30 Nov 2023 Results of pooled analysis assessing effects of canagliflozin on clinical outcomes and intermediate markers of subgroups according to population-specific BMI , from the NCT01032629, NCT01989754 and NCT02065791 studies published in the Diabetes, Obesity and Metabolism.
  • 21 Jul 2023 Results of a pooled post-hoc analysis from two clinical studies: CANVAS Program (NCT01032629 and NCT01989754) CREDENCE (NCT02065791) assessing whether canagliflozin affects risk of non-genital skin and soft tissue infections published in the Diabetes, Obesity and Metabolism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top